ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headache. ShiraTronics is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians.
ShiraTronics is the first spinout from NuXcel a global medical device accelerator company.
ShiraTronics is based in Minneapolis and Ireland.
ShiraTronics is the first spinout from NuXcel a global medical device accelerator company.
ShiraTronics is based in Minneapolis and Ireland.
Location: United States, Minnesota, Minneapolis
Employees: 11-50
Total raised: $102M
Investors 5
| Date | Name | Website |
| - | US Venture... | usvp.com |
| - | Treo Ventu... | treovp.com |
| - | Amzak Heal... | amzakhealt... |
| - | Aperture V... | aperturevp... |
| - | Breakout V... | breakout.v... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 15.10.2024 | Series B | $66M | - |
| 30.03.2020 | Series A | $3M | - |
| 24.10.2019 | Series A | $33M | - |
Mentions in press and media 27
| Date | Title | Description |
| 16.09.2025 | ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Mig... | MINNEAPOLIS, Sept. 16, 2025 /PRNewswire/ -- ShiraTronics, Inc., a clinical-stage medical device company focused on developing novel neuromodulation therapies for chronic migraine, today announced compelling 12-month follow-up data from its ... |
| 11.12.2024 | Summit Spine & Joint Centers First in U.S. to Offer Revolutionary Migraine Treatment | The cost of migraine management in the US is significant. Our goal is to create partnerships with our payors, patients, and physicians to implement a value-based approach to clinical care.” — Dr. Amit Patel, CEO, Summit Spine & Joint Ce... |
| 03.12.2024 | ShiraTronics Initiates IDE Pivotal Study of Implantable Neuromodulation Therapy for Chronic Migraine | - |
| 15.10.2024 | ShiraTronics: A New Dawn for Chronic Migraine Sufferers | Chronic migraines are like shadows that loom over millions, darkening their days and stealing their joy. For those who suffer, the search for relief can feel like an endless journey through a fog. Enter ShiraTronics, a beacon of hope in thi... |
| 15.10.2024 | ShiraTronics: $66 Million (Series B) Raised To Develop Neurostimulation Therapies For Chronic Migraine Patients | ShiraTronics, a clinical-stage medical device company developing neurostimulation therapies for chronic migraine patients, announced the closing of a $66 million Series B financing. The funding round was led by new investor Norwest Venture ... |
| 14.10.2024 | ShiraTronics raises $66M for clinical trials to treat chronic migraines | - |
| 09.10.2024 | ShiraTronics Raises $66M in Series B Financing | ShiraTronics, a Minneapolis, MN-based clinical-stage medical device company, raised $66M in Series B funding. The round was led by Norwest Venture Partners, with participation from additional new investors Seroba., OSF Ventures, the Global ... |
| 09.10.2024 | ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine | Implantable Neuromodulation System Shows Early Promise in Improving Patient Quality of Life by Reducing Monthly Headache Days and Severity of Migraine Attacks MINNEAPOLIS, Oct. 9, 2024 /PRNewswire/ -- ShiraTronics, a clinical-stage medical ... |
| 09.10.2024 | ShiraTronics raises $66M for its neuromodulation implant for chronic migraines | After putting forward preliminary clinical data earlier this year from its neuromodulation implant for reducing chronic migraines, ShiraTronics has raised $66 million in venture capital financing to complete a new pivotal trial and take its... |
| 09.10.2024 | ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine | - |
Show more